A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs AQW 051 (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 17 Jan 2014 Status changed from recruiting to completed as reported by the ClinicalTrials.gov record.
- 15 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 22 Dec 2012 New trial record